Sitagliptin 50 Mg (Generic)

Price range: 90.00$ through 185.00$

Product Overview
Sitagliptin 50 mg is a widely prescribed oral antihyperglycemic agent used in the treatment of Type 2 diabetes mellitus. The medication is produced by Sun Pharmaceutical Industries Ltd, a globally recognized manufacturer with a s

Pack Size	Price	Quantity
100 Tablet/s	90.00$
200 Tablet/s	145.00$
300 Tablet/s	185.00$

Estimated Delivery: Wed, Jun 24 – Fri, Jun 26

... people are viewing this right now

Guaranteed Safe Checkout

🔒 We Accept — Secure International Payment

Bank Transfer

Wire / SWIFT

Zelle

US bank transfer

Crypto

BTC / ETH / USDT

Venmo

US payment app

After placing your order, you will receive full payment details by email. Your order is dispatched within 24 hours of payment confirmation. You can also order directly via WhatsApp for the fastest service.

🚚 Worldwide Shipping — Fully Tracked & Insured

United States

Standard tracked delivery

7–14 Business Days

United Kingdom

Standard tracked delivery

5–10 Business Days

Australia

Standard tracked delivery

10–18 Business Days

Rest of World

50+ countries available

10–20 Business Days

All orders are shipped in plain, discreet packaging with no pharmacy or medicine reference outside. Tracking number is sent by email after dispatch. Shipped from Mumbai, India.

Description

Product Overview

Sitagliptin 50 mg is a widely prescribed oral antihyperglycemic agent used in the treatment of Type 2 diabetes mellitus. The medication is produced by Sun Pharmaceutical Industries Ltd, a globally recognized manufacturer with a strong compliance record. Each strip contains ten immediate‑release tablets, each delivering a precise dose of 50 mg sitagliptin phosphate. The product is packaged in three available pack sizes — 100, 200, and 300 tablets — allowing patients and healthcare providers to select the most appropriate supply for chronic disease management. The formulation is intended for daily use as part of a comprehensive diabetes care plan that includes diet, exercise, and, when necessary, additional pharmacologic therapy.

What is Sitagliptin 50 Mg

Sitagliptin belongs to the class of dipeptidyl peptidase‑4 (DPP‑4) inhibitors, a group of agents that enhance the activity of incretin hormones such as GLP‑1 and GIP. By blocking the DPP‑4 enzyme, sitagliptin slows the degradation of these hormones, leading to increased insulin secretion from pancreatic β‑cells and reduced glucagon release from α‑cells. The 50 mg strength is the standard dose recommended for most adult patients with Type 2 diabetes who do not achieve adequate glycemic control with metformin alone or who require add‑on therapy. The generic version offers the same therapeutic profile as the reference brand, providing cost‑effective access while maintaining the rigorous quality standards expected from a Sun Pharmaceutical product.

Uses and Benefits

The primary use of sitagliptin 50 mg is to improve glycemic control in adults with Type 2 diabetes mellitus, either as monotherapy or in combination with other oral agents or basal insulin. Clinical studies have demonstrated that treatment leads to a modest but clinically significant reduction in fasting plasma glucose and HbA1c levels, markers that are closely linked to long‑term cardiovascular and renal outcomes. Patients often experience fewer episodes of hypoglycemia compared with sulfonylureas, and the drug is generally well‑tolerated. Additional benefits include weight neutrality, meaning most users do not experience significant weight gain, and a low propensity for drug‑drug interactions when used according to recommended guidelines.

How It Works

At the molecular level, sitagliptin inhibits the DPP‑4 enzyme that rapidly cleaves incretin hormones after they are released in response to food intake. This inhibition prolongs the activity of GLP‑1 and GIP, which in turn stimulate glucose‑dependent insulin secretion and suppress hepatic glucose production. The glucose‑dependent nature of the drug’s action means that it enhances insulin release only when blood glucose is elevated, thereby reducing the risk of hypoglycemia. Pharmacokinetic data show that sitagliptin is absorbed orally with an onset of action within one to two hours, reaches peak plasma concentrations after approximately one hour, and is eliminated primarily through renal pathways, with a half‑life of about five hours. Mechanistic details are consistent with data from the National Institutes of Health (NIH).

Dosage Guidelines

Patients are typically instructed to take one 50 mg tablet once daily, with or without food, at the same time each day to maintain consistent drug levels. The prescribing information advises that dose adjustments are not required for most patients with mild to moderate renal impairment, but a reduced dose may be considered in individuals with severe renal dysfunction (creatinine clearance <30 mL/min). The medication should be integrated into a broader therapeutic regimen that includes lifestyle modifications such as balanced nutrition and regular physical activity. Healthcare providers may reassess glycemic response after several weeks and adjust the treatment plan accordingly, ensuring that the patient stays within the target glucose range defined by their clinician.

Side Effects

Like all pharmaceutical agents, sitagliptin can be associated with adverse events, although most are mild and transient. The most commonly reported side effects include upper respiratory tract infections, headache, and mild gastrointestinal discomfort such as nausea or diarrhea. Less frequent but clinically important reactions may involve pancreatitis, allergic skin eruptions, or rare cases of severe hypersensitivity. Patients should be counseled to report persistent or worsening symptoms, particularly signs of pancreatitis such as severe abdominal pain radiating to the back, vomiting, or a rapid increase in serum lipase levels. Routine laboratory monitoring is not mandatory, but periodic assessment of kidney function is recommended for those with pre‑existing renal disease. Information on regulatory oversight can be found at U.S. Food and Drug Administration.

Warnings and Precautions

Prior to initiating therapy, clinicians should evaluate patients for a history of pancreatitis, severe renal impairment, or known hypersensitivity to sitagliptin or any component of the formulation. Caution is advised in patients with a history of alcohol abuse or those concurrently using other medications that may affect renal function. The drug should be used with care in pregnant or breastfeeding women only when the potential benefit justifies the potential risk, and a discussion with a qualified healthcare professional is essential. Additionally, prescribers should be aware that the medication may enhance the effect of certain combination products containing sitagliptin, and patients should be instructed not to self‑medicate with over‑the‑counter products that contain the same active ingredient.

Frequently Asked Questions

Q: What is the recommended starting dose? A: The usual starting dose is one 50 mg tablet daily; dosage may be adjusted by a clinician based on kidney function and response.

Q: Can sitagliptin be taken with insulin? A: Yes, it can be used together with basal insulin, but blood glucose monitoring should be increased to avoid hypoglycemia.

Q: Is the medication safe for older adults? A: Clinical data support its use in older patients, provided renal function is evaluated and dose adjustments are made if needed.

Q: How long does it take to see improvements in blood sugar? A: Patients often notice a reduction in fasting glucose within a few weeks, with full HbA1c effects observed after 12‑24 weeks of consistent therapy.

Q: Are there dietary restrictions while on sitagliptin? A: No specific dietary restrictions are required; however, a balanced diet and regular exercise enhance overall glycemic control.